SYMJEPI
Peakepinephrine
NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Clinical Trials (5)
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Started Nov 2024
2,800 enrolled
Septic Shock
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Started Aug 2024
520 enrolled
Excessive SleepinessShift-work Disorder
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Started Apr 2024
450 enrolled
Binge-Eating Disorder
Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Started Mar 2024
346 enrolled
Major Depressive Disorder
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.
Started Oct 2023
24 enrolled
Anaphylactic Reaction
Loss of Exclusivity
LOE Date
Oct 20, 2036
129 months away
Patent Expiry
Oct 20, 2036
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 11141540 | Oct 20, 2036 | Product | U-3379 |